National Eye Institute

Digital home monitoring shows unique predictive value in disease progression for AMD patients

Retrieved on: 
Martedì, Ottobre 25, 2022
Physician, Time, Insurance, Risk, Disease, Claysburg-Kimmel School District, OCT, Alarm monitoring center, Diagnosis, Review, Choroidal neovascularization, National Eye, Patient, NOA, HIV disease progression rates, Home, HOME, Thomas Jefferson University, Severe cognitive impairment, Monitoring, Google Images, Analysis, Medicare, Doctor of Philosophy, AI, CNV, Health, PHP, GLOBE, National Eye Institute, FDA, Home Monitoring Aréna, Inc., AMD, Medical device, Pharmaceutical industry, Medical imaging, Ophthalmology, Retina, MD, Eye

These patients were twice as likely than other dry AMD patients to convert over the same period.

Key Points: 
  • These patients were twice as likely than other dry AMD patients to convert over the same period.
  • The predictive nature of alerts from the AI-enabled ForeseeHome can be invaluable for studying prophylactic treatments for AMD patients.
  • The Notal Vision Monitoring Center is the only ophthalmic digital health provider offering remote monitoring for qualified AMD patients.
  • The ForeseeHome AMD Monitoring Program is a comprehensive program, which includes an FDA-cleared device that monitors visual changes in intermediate dry AMD patients at risk of vision loss from undiagnosed wet AMD.

Global Medical Electrodes Market Report to 2031 - Players Include 3M, Koninklijke Philips, Medtronic and Natus Medical - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Ottobre 24, 2022
Medical Supplies, Health, NSF, Prevalence, Growth, NEI, National Eye Institute, Diagnosis, Cardiology, CAGR, Nanotechnology, Porter's five forces analysis, National Science Foundation, Parkinson's disease, DE, Department, Application, Miniaturization, Alzheimer's disease, Medicine, Government, Lists of countries and territories, Benchmarking, Medical device

The global medical electrodes market was valued at $1,676.2 million in 2021, and is projected to reach $2,387.35 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.

Key Points: 
  • The global medical electrodes market was valued at $1,676.2 million in 2021, and is projected to reach $2,387.35 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.
  • In addition, in the U.S., medical reimbursement policies include major medical electrodes, which augment the growth of this market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the medical electrodes market analysis from 2021 to 2031 to identify the prevailing medical electrodes market opportunity.
  • The report includes the analysis of the regional as well as global medical electrodes market trends, key players, market segments, application areas, and market growth strategies.

NEXGEL Develops New Hydrogel Patch to Treat Amblyopia

Retrieved on: 
Giovedì, Ottobre 20, 2022
Health, Time, Securities Act of 1933, SEC, National Eye Institute, Amblyopia, Population, NASDAQ, Annual report, Patient, Gel, Hydrogel, Eye, Private Securities Litigation Reform Act, Company, Learning, Irritation, Visual impairment, Pain, Nature, Intention, Securities Exchange Act of 1934, Ophthalmology, Skin, GLOBE, COVID-19, Risk, Cosmetics

LANGHORNE, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that it has developed a new, proprietary hydrogel eye patch to treat amblyopia, a type of poor vision that typically occurs in one eye but can occur in both eyes (also called lazy eye). The patch is expected be available for ophthalmologists and optometrists to offer to their patients in the first half of 2023.

Key Points: 
  • LANGHORNE, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NEXGEL or the Company) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that it has developed a new, proprietary hydrogel eye patch to treat amblyopia, a type of poor vision that typically occurs in one eye but can occur in both eyes (also called lazy eye).
  • The patch is expected be available for ophthalmologists and optometrists to offer to their patients in the first half of 2023.
  • The global amblyopia treatment market is also expected to reach over $ 6 billion by 2027.
  • Unlike the current standard-of-care patching for amblyopia, NEXGELs hydrogel patch is much gentler on the skin and is manufactured without the use of harsh chemicals or painful adhesives.

Innovega Signs Smart Glasses Letter of Intent with Global Electronics Supplier

Retrieved on: 
Giovedì, Ottobre 20, 2022
Medicine, National Eye Institute, Virtual reality, AR, Smartglasses, Lens (anatomy), DARPA, Investment, Technology, National, Patent, National Science Foundation, Intention, GLOBE, Letter, Image, Television, Metaverse

Innovega selected this company for its unique ability to design and manufacture precision components needed to deliver the quality of smart glasses designed for comfort and performance.

Key Points: 
  • Innovega selected this company for its unique ability to design and manufacture precision components needed to deliver the quality of smart glasses designed for comfort and performance.
  • This is Innovegas second Letter of Intent for evaluating opportunities for its next-generation display eyewear that is protected by 69 filed patent cases.
  • Our product licensing model for Innovegas smart contact lenses and smart glasses allows the Innovega team to remain focused on delivering world-class innovation.
  • Innovegas display system includes patented disposable soft smart contact lenses that are used in conjunction with its smart display glasses.

Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease

Retrieved on: 
Lunedì, Ottobre 3, 2022
Health, Diabetes, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Doctor of Philosophy, Trial of the century, Unitary state, Drug development, Office of Inspector General, U.S. Department of Health and Human Services, Disease, ABCA4, Clinical trial, Kubota, Life, RPE65, CEO, Emixustat, Population, MD, Retina, OCT, FDA, View, Severe cognitive impairment, Eye, HHS, Anetoderma, National Eye Institute, Treatment, Patient, Neurodegeneration, Month, RESEARCH, EMA, Government, Company, Vitamin A, Pharmaceutical industry, Stargardt disease

Kubota Vision Inc. (Kubota Vision), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease.
  • This analysis determined that emixustat treatment resulted in a 40.8% reduction in lesion progression compared to placebo at Month 24 (p=0.0206, emixustat n=34, placebo n=21).
  • As previously announced in August 2020, the FDA Office of Orphan Products Development (OOPD) awarded Kubota Vision an orphan products clinical trial grant to support this clinical trial.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Global Intraocular Lens Market Report to 2031 - Players Include Alcon, Bausch Health, Carl Zeiss Meditech and Hoya - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Settembre 29, 2022
Health, Optical, Diabetes, Adoption, Porter's five forces analysis, Incidence, Sorbitol, Risk, Prevalence, Congenital cataract, National Eye Institute, National Center for Biotechnology Information, Astigmatism, Growth, Partnership, Myopia, Government, Cataract, Patient, Presbyopia, Johnson & Johnson, Eye, NCBI, Approximation error, Severe cognitive impairment, Benchmarking, US, Diabetic retinopathy, Megasphaera, National Center on Education and the Economy, CAGR, Retail, Telescopic sight, Pharmaceutical industry

The intraocular lens market was valued $3,777.16 million in 2021 and is expected to reach $6,535.51 million by 2031, growing at a CAGR of 5.6% from 2022 to 2031.

Key Points: 
  • The intraocular lens market was valued $3,777.16 million in 2021 and is expected to reach $6,535.51 million by 2031, growing at a CAGR of 5.6% from 2022 to 2031.
  • Increase in prevalence of cataract and rise in initiatives taken by government to eliminate avoidable blindness drive the growth of the global intraocular lens market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the intraocular lens market analysis from 2021 to 2031 to identify the prevailing intraocular lens market opportunities.
  • The report includes the analysis of the regional as well as global intraocular lens market trends, key players, market segments, application areas, and market growth strategies.

Radius XR, a new fashion-forward wearable technology brand, brings together multimodal diagnostics, practice management, and patient engagement for the first time

Retrieved on: 
Mercoledì, Settembre 28, 2022
Hardware, Retail, Other Professional Services, Data Management, Consumer Electronics, Technology, Practice Management, Professional Services, Online Retail, Seniors, Software, Consumer, Health, Mobile, Wireless, Medical Supplies, American Academy, AAO, Radius, IrisVision, AR, Eye, Vision, Deming, National Eye Institute, Visual acuity, Color scheme, Life, Booth, Industry, Gold, Severe cognitive impairment, Patient, CES, Leadership, Johns Hopkins University, Diagnosis, Stanford University, Business suite, Research, Ageing, Visual field, American Academy of Ophthalmology, View, Pharmaceutical industry, Medical device, Medicine

Radius XR builds on the therapeutic legacy of IrisVision by introducing diagnostic capability to the proprietary VR/AR assistive device.

Key Points: 
  • Radius XR builds on the therapeutic legacy of IrisVision by introducing diagnostic capability to the proprietary VR/AR assistive device.
  • Using a single Radius XR headset, patients can self-perform a range of vision tests that are clinically equivalent to gold standard exams.
  • The exams currently performed with the Radius XR testing platform are Visual Field, Visual Acuity, Contrast Sensitivity, Amsler Grid, and Color Scheme.
  • Radius XR is the industrys lightest wearable device, weighing just under 6 oz., and features all-day battery life.

Global Retinal Surgery Devices Market Analysis Report 2022-2027: Major Company Profiles, Deals, Strategies, Growth Drivers and Recent Developments - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Settembre 28, 2022
Health, Optical, Surgery, Retinal, Diabetes, Therapy, Incidence, Alcon, COVID-19, Epiretinal membrane, FDA, Food, Prevalence, LLC, National Eye Institute, Acquisition, Bausch & Lomb, Compliance, Growth, Center for Urban and Regional Analysis, Retina, Ophthalmology, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, MIGS, OVD, Severe cognitive impairment, Diabetic retinopathy, Vitrectomy, Percussion section, Retinal detachment, Pharmaceutical industry, Dentistry, Health insurance, Medical device, Application, Ivanti

The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Among the device types, vitrectomy packs segment accounts for the largest revenue share in the global retinal surgery devices market.
  • Vitrectomy machines segment captured second highest share of the global retinal surgery devices market in 2021, being followed by Retinal lasers device segment.
  • Latin America and Middle East and Africa are competing closely to grab maximum share of the retinal surgery devices market.

Retinal Surgery Devices Market Report 2022: Increasing Demand for Minimally Invasive Surgeries Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Settembre 22, 2022
Health, Optical, Surgery, International Diabetes Federation, Blurred, Retina, Adoption, Cryotherapy, COVID-19, Prevalence, World, World Health Organization, National Eye Institute, Population, Diabetes, History, Eye, Blood, Diabetic retinopathy, IDF, WHO, PDR, Ageing, CAGR, Pharmaceutical industry, Dentistry, Growth

The "Retinal Surgery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinal Surgery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • Retinal surgical devices are used to repair retinal torn or detached retinas in procedures such as laser surgery, cryotherapy, scleral buckle surgery etc.
  • Increasing prevalence of diabetes, retinal disorders, eye injuries and rising geriatric population are the key driving factors in the retinal surgery devices market.
  • Furthermore, rise in the adoption of advanced technologies in retinal surgery devices and growing number of minimally invasive surgeries is fueling the growth of the overall regional market to a large extent.

NewHaptics Awarded NIH SBIR Phase II Grant to Commercialize Multiline Braille and Graphical Tactile Display

Retrieved on: 
Giovedì, Settembre 15, 2022
University, Twitter, ANN, National Eye Institute, LinkedIn, Company, Severe cognitive impairment, Technology, National Science Foundation, SBIR, Quality of life, National Research Council Canada National Science Library, Research, NIH, Pharmaceutical industry, Television

ANN ARBOR, Mich., Sept. 15, 2022 /PRNewswire/ -- NewHaptics, an innovative tactile display technology company, announced it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH). The competitive $1.7M grant was awarded by the National Eye Institute, which aims to eliminate vision loss and improve quality of life through vision research. This is the third SBIR award received by NewHaptics to date, and supports the company's development of novel tactile display technology for a low-cost multiline refreshable braille display for the blind.

Key Points: 
  • ANN ARBOR, Mich., Sept. 15, 2022 /PRNewswire/ -- NewHaptics, an innovative tactile display technology company, announced it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH).
  • This is the third SBIR award received by NewHaptics to date, and supports the company's development of novel tactile display technology for a low-cost multiline refreshable braille display for the blind.
  • The Company's patented tactile display technology enables the creation of a compact, portable, and large-area tactile "screen."
  • Unlike the state-of-the-art technology for existing refreshable braille displays, NewHaptics' technology can scale up to a large-area display supporting a grid of thousands of small tightly-packed tactile dots.